BioCentury
ARTICLE | Tools & Techniques

Silencing KRAS

January 9, 2014 8:00 AM UTC

Oncogenic KRAS is notoriously difficult to target because of a lack of well-defined surface pockets for drug binding. Nucleic acid therapeutics can bypass that issue but have their own problems including tissue targeting, cellular uptake and degradation in the blood. Silenseed Ltd. thinks it has addressed the issues of the latter modality with a localized, sustained siRNA delivery technology dubbed LODER.1

A paper in the Proceedings of the National Academy of Sciences provides the first detailed look at the technology and suggests that delivery of siRNA targeting KRAS (K-Ras) using LODER (local drug eluter) may cause pancreatic tumor regression...